Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock. HC Wainwright also issued estimates for Anixa Biosciences’ FY2024 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.12) […]

Leave a Reply

Your email address will not be published.

Previous post Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com
Next post The Goldman Sachs Group Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $200.00